Core Viewpoint - Sino Medical achieved a significant stock price increase of 19.99% on August 18, reaching a price of 41.48 CNY per share, with a trading volume of 2.032 billion CNY and a turnover rate of 12.37%, resulting in a total market capitalization of 17.258 billion CNY [1] Company Overview - Sino Medical Technology Co., Ltd. is located in the Tianjin Economic-Technological Development Area and specializes in the research, production, and sales of high-end interventional medical devices [1] - The company’s main products include coronary drug-eluting stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents, with over 1.4 million units used globally, serving hundreds of thousands of patients [1] - Sino Medical holds 8 key technologies, has launched 19 products, and possesses over 200 global patents, while undertaking 7 national and provincial scientific research projects [1] - Clinical research results of its products have been published in 31 articles in core domestic and international journals [1] Financial Performance - For the period from January to March 2025, Sino Medical reported a revenue of 101 million CNY, representing a year-on-year growth of 10.75% [1] - The net profit attributable to shareholders was 2.9693 million CNY, showing a substantial year-on-year increase of 277.50% [1] - As of March 31, the number of shareholders was 11,000, with an average of 37,400 circulating shares per person [1]

Core Viewpoint - Sino Medical achieved a significant stock price increase of 19.99%, reaching 30.13 CNY per share, with a trading volume of 3.005 billion CNY and a turnover rate of 26.34%, resulting in a total market capitalization of 12.536 billion CNY [1] Company Overview - Sino Medical Science and Technology Co., Ltd. is located in Tianjin Development Zone and specializes in the research, production, and sales of high-end interventional medical devices [1] - The company’s main products include coronary drug-eluting stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents, with over 1.4 million units used globally, serving hundreds of thousands of patients [1] - Sino Medical holds 8 key technologies, has launched 19 products, and possesses over 200 global patents, while undertaking 7 national and provincial scientific research projects [1] - Clinical research results have been published in 31 articles in core domestic and international journals [1] Financial Performance - For the first quarter of 2025, Sino Medical reported a revenue of 101 million CNY, representing a year-on-year growth of 10.75% [1] - The net profit attributable to shareholders was 2.9693 million CNY, showing a substantial year-on-year increase of 277.50% [1] - As of March 31, the number of shareholders was 11,000, with an average of 37,400 circulating shares per person [1]

Core Viewpoint - The company, Sainuo Medical Technology Co., Ltd., is expected to achieve significant growth in its half-year performance for 2025, with notable increases in both revenue and net profit [1][3]. Financial Performance Summary - The company anticipates a revenue of 240 million yuan for the first half of 2025, representing an increase of 26.78 million yuan or 12.53% compared to 214 million yuan in the same period last year [3]. - The net profit attributable to shareholders is projected to be 13.84 million yuan, a substantial increase of 10.35 million yuan or 296.54% from 3.49 million yuan year-on-year [3]. - The net profit after deducting non-recurring gains and losses is expected to be 7.98 million yuan, an increase of 20.57 million yuan or 163.35% from a loss of 12.59 million yuan in the previous year [3]. Growth Drivers - The significant growth in revenue is primarily driven by the increased sales of two coronary stent products and coronary balloon products that entered the centralized procurement range [10]. - The neuro-interventional business has shown steady growth, further contributing to the overall performance [10]. - Although operating costs have increased slightly year-on-year, reductions in sales and R&D expenses have effectively lowered overall costs [10]. - Management expenses have increased year-on-year, but a significant decrease in investment income and asset impairment losses has also contributed to profit growth [10]. Company Overview - Sainuo Medical, established on September 21, 2007, focuses on the research, development, production, and sales of high-end interventional medical devices [5]. - The company is headquartered in Tianjin and has subsidiaries in various locations including Beijing, Suzhou, Hong Kong, the United States, Japan, the Netherlands, and France [5]. - The main business areas include interventional treatment for cardiovascular, cerebrovascular, and structural heart diseases, with key products such as drug-eluting stents and balloon dilation catheters [5][6]. - The company has established a comprehensive quality management system and has received ISO 13485:2016 certification [7].

Core Points - The company, Sino Medical Science and Technology Co., Ltd., is preparing for its 2024 Annual General Meeting (AGM) to ensure the rights of all shareholders and maintain order during the meeting [1][2][3] - The company reported a significant increase in revenue and net profit for 2024, with total assets reaching 1.3 billion yuan and net assets of 898 million yuan [8][9][10] - The company achieved a revenue of 459 million yuan, a year-on-year increase of 33.64%, and a net profit attributable to shareholders of 1.4978 million yuan, up 103.78% [8][10][12] - The company has established a strong international presence, with its products registered in 26 countries and regions, and overseas sales revenue growing by 72.38% [13][14] Meeting Procedures - The AGM will be held on May 19, 2025, with both on-site and online voting options available for shareholders [5][6] - Shareholders must arrive 30 minutes before the meeting to complete registration and present necessary documentation [2][3] - The meeting will follow a structured agenda, including the announcement of attendees, discussion of proposals, and voting [7][8] Financial Performance - The company reported total assets of 1.3 billion yuan and total liabilities of 402 million yuan, reflecting a 9.68% and 24.08% increase year-on-year, respectively [9][10] - The company’s main products, including coronary drug-eluting stents and intracranial stents, have seen significant sales growth, with coronary business revenue increasing by 59.19% [12][14] - The company has focused on innovation, with 22 new patents granted during the reporting period, enhancing its competitive edge in the medical device market [14][15] Governance and Compliance - The board of directors has held six meetings in 2024, ensuring compliance with relevant laws and regulations [24][30] - The company emphasizes the importance of independent directors, with three independent directors actively participating in board meetings [24][30] - The company has implemented robust internal controls to manage risks and ensure compliance with financial regulations [31]

正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 赛诺医疗科学技术股份有限公司 （股票代码：688108.SH）成立于2007年9月21日，是一家专注于高端介入 医疗器械研发、生产及销售的国际化公司。公司总部位于天津经济技术开发区，同时在北京、苏州、香港、美 国、日本、荷兰、法国等地设有子公司。公司于2019年10月30日在上海证券交易所科创板上市。 赛诺医疗的主营业务涵盖 心血管、脑血管及结构性心脏病 等介入治疗领域的高端医疗器械研发、生产和销 售。公司的主要产品包括： 2025年4月26日， 赛诺医疗 发布了2024年年报。 | 主要会计数据 | 2024年 | 2023年 | 本期比上年同期 | 2022年 | | --- | --- | --- | --- | --- | | | | | 增减(%) | | | 营业收入 | 458,739,271.36 | 343,257,735.55 | 33.64 | 192,854,227.69 | | 扣除与主营业务无关的业务收入和不具备商 业实质的收入后的营业收入 | 457,942,375.80 | 340,02 ...